A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES)

European Organisation for research and treatment of Cancer0 个研究点目标入组 0 人开始时间: 2019年3月27日最近更新: 2024年3月12日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Women or men with pathologic stage II or stage III, early invasive breast cancer
•according to the UICC 8th edition for TNM classification
•- Histologically confirmed ER+ (at least 10 % of cells staining positive
•for ER), HER-2 negative, early invasive breast cancer based on results of
•local pathology. Testing may be performed on diagnostic core biopsy or
•resection specimen.
•- In patients with multicentric, multifocal and/or bilateral breast cancer,
•all histopathologically examined invasive tumors must meet pathologic
•criteria regarding ER and HER2-status described above.
•- Adjuvant chemotherapy indicated and feasible according to treating
•physician and patient, based on standard clinicopathological parameters
•(tumor size, lymph node involvement, general health status,
•proliferation marker, patient wish) and gene expression profile if
•- Adjuvant chemotherapy with both anthracycline and taxanes (in
•combination or in sequence) considered not indicated or not feasible
•according to treating physician.
•- Age =70 years
•- WHO Performance status 0-2
•- Completed G8 geriatric assessment within 3 weeks of randomization.
•- Participation in translational research is mandatory and therefore
•patient must consent for it. Patient should allow sequential sampling of
•blood during the course of the trial
•- Patient must have undergone breast +/- axillary surgery with curative
•intent for the current malignancy =12 weeks before randomization. The
•final primary tumor surgical specimen must have R0 margins free from
•- Patients must have sufficient resolution of any surgical side effects
•from the last surgery per physician assessment, with no active wound
•healing complications at the time of randomization.
•- Incentive to undergo adjuvant radiation therapy when indicated per
•local institutional guidelines.
•Note: For patients in the palbociclib arm, radiation therapy when
•indicated has to start =13 weeks after last surgery. The endocrine
•therapy can be initiated during or after the radiation therapy but not
•later than 4 weeks after the last radiotherapy. Palbociclib has to start =4
•weeks after the last radiotherapy. When radiation therapy is not
•indicated, endocrine therapy and palbociclib have to be initiated =13
•weeks after last surgery. Note: For patients in the chemotherapy arm,
•chemotherapy has to be the first adjuvant treatment and has to start =
•13 weeks after the last surgery. When radiation therapy is indicated, this
•treatment has to start =9 weeks after the last chemotherapy
•administration. Adjuvant endocrine therapy can be initiated during or
•after the radiation therapy but not later than 4 weeks after the last
•radiotherapy. When radiation therapy is not indicated, endocrine therapy
•has to be initiated =6 weeks after last chemotherapy administration.
•- Adequate baseline organ function, evidenced by the following
•laboratory results within 3 weeks of randomization:
•- Hemoglobin = 9 g/dL
•- Absolute neutrophil count (ANC) = 1500/mm3
•- Platelet count = 100,000/mm3
•- Total bilirubin = 1.5 upper limit of normal (ULN), or total bilirubin = 3.0
另有 7 项未显示

排除标准

•- Evidence of macroscopic distant metastases, investigated according to
•local institutional guidelines.
•- Previous history of invasive breast cancer
•- Systemic anticancer therapy prior to the breast cancer surgery
•- Prior therapy with any CDK4/6 inhibitor
•- Concurrent investigational agent within 28 days of randomization or
•five elimination half-lives, whichever is longer
•- Concomitant anticancer treatment with the exception of bone
•antiresorptive agents or LHRH agonists in male patients treated with an
•aromatase-inhibitor
•- History of allergic reactions attributed to compounds of chemical or
•biological composition similar to palbociclib or to chemotherapy
•- Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
•- Medications or substances that are potent inhibitors or inducers of
•CYP3A isoenzymes within 7 days of randomization
•- History of extensive disseminated/bilateral or known presence of
•interstitial fibrosis or interstitial lung disease, including a history of
•pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia,
•interstitial lung disease, obliterative bronchiolitis, and pulmonary
•fibrosis, but not history of prior radiation pneumonitis.
•- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including known HIV, active hepatitis B and/or
•hepatitis C infection), symptomatic congestive heart failure, unstable
•angina pectoris, uncontrolled cardiac arrhythmia, or uncontrolled
•Note: For patients for whom doxorubicin or epirubicin is planned, an
•adequate baseline cardiac function (left ventricular ejection fraction =
•50%) should have been proven no more than 1 year before treatment
•- Any psychological, familial, sociological or geographical condition
•potentially hampering compliance with the study protocol and follow-up
•schedule; those conditions should be discussed with the patient before
•registration in the trial
•- Other malignancy within the last 5 years except: adequately treated
•non-metastatic non-melanoma skin cancer, or successfully treated in situ carcinoma for example curatively treated in situ
•cancer of the cervix, ductal carcinoma in situ of the breast.

研究者

发起方

European Organisation for research and treatment of Cancer

相似试验

进行中（未招募）

1 期

A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapse

EUCTR2018-002553-30-ESEuropean Organisation for research and treatment of Cancer366

进行中（未招募）

1 期

A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapseocalized ER+ breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: LLTClassification code 10070577Term: Oestrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10006291Term: Breast neoplasms malignant and unspecified (incl nipple)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-002553-30-DEEuropean Organisation for research and treatment of Cancer

进行中（未招募）

1 期

EUCTR2018-002553-30-ITEORTC AISBL/IVZW366

进行中（未招募）

1 期

EUCTR2018-002553-30-PTEuropean Organisation for research and treatment of Cancer

进行中（未招募）

1 期

A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapse

EUCTR2018-002553-30-SEEuropean Organisation for research and treatment of Cancer366